of Annual Revenues over
the last 29 years1
of Net Profit over the
last 29 years1
to shareholders over the
last 29 years2
of the Company
Capital returned to
through dividends and buybacks
Total value created
1. 1988 revenue and PAT numbers were for the year ending June 30, 1988. 1988 numbers are as per Indian GAAP; FY2017 numbers are reported as per IndAS.
2. Total shareholder returns compounded annually from Factset as on May 19, 2017 (assumed dividend reinvested in the stock on ex dividend date, price adjusted for stock splits and special dividend)
3. Market capitalisation as on May 19, 2017
At Piramal Enterprises, creating value for all stakeholders, including our shareholders has been a defining element of our identity. Over the past 29 years, since the acquisition of Nicholas Laboratories, we have delivered annualised shareholder returns of 30%.
Our purpose at the Piramal Group
DOING WELL AND DOING GOOD
PEL’s Financial Services segment offers a comprehensive suite of financial products to meet the diverse and evolving needs of its customers. The Company has created its unique positioning in the financial services space through its strong presence in the following sub-segments.
PEL’s Healthcare Insight and Analytics business, Decision Resources Group (DRG), is a best-in-class, decision support platform in the healthcare information services space.
It provides indispensable insights to life sciences companies, and healthcare providers and payers, through a variety of high value-added data and analytics, research reports and knowledge-based services. These offerings enable customers to make informed investment, cost containment, commercial optimisation and strategic business decisions in their chosen markets.
GROWTH IN REVENUES
TO ` 8,547 CRORES
GROWTH IN NET PROFIT
TO ` 1,252 CRORES
GROWTH IN TOTAL ASSETS
TO ` 48,239 CRORES
87% Growth in Loan Book
20% Global Pharma EBITDA margin
HEALTHCARE INSIGHT AND ANALYTICS
250+ positions on-boarded in India offices